The numbers are good. If you go & look at some post hoc analysis of Cana, there was a broad range in reduction of UACR dependent on starting baseline.
The subgroup in DKD DMX-200 trial 500mg/L or greater achieved a 37-38% reduction in UACR. Compare that to the above of 31% at week 26 with a cohort of >300mg/L. We know from the CREDENCE trial that UACR & eGFR decline & then plateau at 26 weeks.
I’m sure there is loads to discuss here, catch up later
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-19
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.020(6.45%) |
Mkt cap ! $184.0M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 33.8¢ | 31.0¢ | $461.5K | 1.415M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 57518 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 15093 | 2 |
View Market Depth
| Last trade - 16.10pm 27/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |
